This company listing is no longer active
IVERIC bio Crecimiento futuro
Future controles de criterios 5/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for IVERIC bio.
Información clave
59.0%
Tasa de crecimiento de los beneficios
61.5%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 30.8% |
| Tasa de crecimiento de los ingresos | 58.0% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | 23 Jun 2023 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2025 | 365 | -28 | 57 | N/A | 9 |
| 12/31/2024 | 124 | -200 | -131 | -154 | 9 |
| 12/31/2023 | 11 | -281 | -212 | -236 | 8 |
| 3/31/2023 | N/A | -223 | -178 | -177 | N/A |
| 12/31/2022 | N/A | -185 | -165 | -164 | N/A |
| 9/30/2022 | N/A | -159 | -138 | -137 | N/A |
| 6/30/2022 | N/A | -141 | -123 | -122 | N/A |
| 3/31/2022 | N/A | -122 | -107 | -107 | N/A |
| 12/31/2021 | N/A | -115 | -99 | -99 | N/A |
| 9/30/2021 | N/A | -107 | -97 | -97 | N/A |
| 6/30/2021 | N/A | -108 | -86 | -86 | N/A |
| 3/31/2021 | N/A | -96 | -78 | -78 | N/A |
| 12/31/2020 | N/A | -85 | -66 | -66 | N/A |
| 9/30/2020 | N/A | -77 | -57 | -57 | N/A |
| 6/30/2020 | N/A | -66 | -54 | -54 | N/A |
| 3/31/2020 | N/A | -61 | -51 | -51 | N/A |
| 12/31/2019 | N/A | -59 | -48 | -48 | N/A |
| 9/30/2019 | N/A | 63 | -47 | -47 | N/A |
| 6/30/2019 | N/A | 62 | -45 | -45 | N/A |
| 3/31/2019 | N/A | 64 | -44 | -44 | N/A |
| 12/31/2018 | N/A | 63 | -42 | -42 | N/A |
| 9/30/2018 | N/A | -51 | -45 | -45 | N/A |
| 6/30/2018 | 207 | 153 | -50 | -50 | N/A |
| 3/31/2018 | 208 | 144 | -72 | -72 | N/A |
| 12/31/2017 | 210 | 114 | -122 | -122 | N/A |
| 9/30/2017 | 215 | 57 | -142 | -141 | N/A |
| 6/30/2017 | 10 | -192 | -132 | -131 | N/A |
| 3/31/2017 | 37 | -200 | -134 | -133 | N/A |
| 12/31/2016 | 51 | -193 | N/A | -109 | N/A |
| 9/30/2016 | 50 | -163 | N/A | -115 | N/A |
| 6/30/2016 | 52 | -141 | N/A | -133 | N/A |
| 3/31/2016 | 26 | -149 | N/A | -84 | N/A |
| 12/31/2015 | 52 | -106 | N/A | -79 | N/A |
| 9/30/2015 | 48 | -102 | N/A | -29 | N/A |
| 6/30/2015 | 85 | -54 | N/A | -50 | N/A |
| 3/31/2015 | 83 | -89 | N/A | 96 | N/A |
| 12/31/2014 | 41 | -117 | N/A | 111 | N/A |
| 9/30/2014 | 40 | -106 | N/A | 75 | N/A |
| 6/30/2014 | N/A | -132 | N/A | 107 | N/A |
| 3/31/2014 | N/A | -71 | N/A | -61 | N/A |
| 12/31/2013 | N/A | -57 | N/A | -49 | N/A |
| 9/30/2013 | N/A | -42 | N/A | -27 | N/A |
| 6/30/2013 | N/A | -30 | N/A | -18 | N/A |
| 3/31/2013 | N/A | -23 | N/A | -13 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: O2T is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Beneficios vs. Mercado: O2T is forecast to become profitable over the next 3 years, which is considered above average market growth.
Beneficios de alto crecimiento: O2T is expected to become profitable in the next 3 years.
Ingresos vs. Mercado: O2T's revenue (58% per year) is forecast to grow faster than the German market (3.3% per year).
Ingresos de alto crecimiento: O2T's revenue (58% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if O2T's Return on Equity is forecast to be high in 3 years time